ReNewVax
Startup
ReNewVax has developed a vaccine discovery platform based on the exploitation of genomic analysis and ex vivo human predictive models. Our lead program, RVX-001, is a best-in-class vaccine designed to induce universal immunity against pneumococcus infection, the most common cause of bacterial pneumonia and the largest pre-pandemic vaccine market. Programs for Group A and Group B Streptococcus are also in the ReNewVax pipeline – key pathogens in the fight against AntiMicrobial Resistance (AMR).
Research targeted at reducing the global burden of pneumococcal diseases has led to the development of vaccines such as PPSV-23 (Merck), PCV-13 (Pfizer), and others. These vaccines have had a major impact, and before the pandemic, pneumococcal vaccines had become the largest global vaccine market with annual sales of around £7bn in 2020 and projected to reach £14.7bn by 2027. Although existing vaccines have proven to be effective at reducing the occurrence of pneumococcal disease, they are only effective against the limited number of pneumococcal strains that they cover, they rely on technology that unfortunately makes them costly to manufacture and crucially, limits their ability to protect against all 100+ known pneumococcal strains.
RVX-001 works in a completely different manner to existing pneumococcal vaccines. Instead of targeting the sugar molecules on the outside of the bacteria - which vary from strain to strain, thus limiting the range of protection, RVX-001 was designed to target highly conserved proteins that are present on all 100 strains of pneumococcus. Preclinical studies have provided robust proof-of-concept for RVX-001 and work is ongoing to consolidate our pre-CTA package. Initial clinical trials will commence in 2025.
Research targeted at reducing the global burden of pneumococcal diseases has led to the development of vaccines such as PPSV-23 (Merck), PCV-13 (Pfizer), and others. These vaccines have had a major impact, and before the pandemic, pneumococcal vaccines had become the largest global vaccine market with annual sales of around £7bn in 2020 and projected to reach £14.7bn by 2027. Although existing vaccines have proven to be effective at reducing the occurrence of pneumococcal disease, they are only effective against the limited number of pneumococcal strains that they cover, they rely on technology that unfortunately makes them costly to manufacture and crucially, limits their ability to protect against all 100+ known pneumococcal strains.
RVX-001 works in a completely different manner to existing pneumococcal vaccines. Instead of targeting the sugar molecules on the outside of the bacteria - which vary from strain to strain, thus limiting the range of protection, RVX-001 was designed to target highly conserved proteins that are present on all 100 strains of pneumococcus. Preclinical studies have provided robust proof-of-concept for RVX-001 and work is ongoing to consolidate our pre-CTA package. Initial clinical trials will commence in 2025.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events